Related references
Note: Only part of the references are listed.Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Herve Tilly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients
Sara Harrysson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study
Ron Ram et al.
HAEMATOLOGICA (2022)
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Toby A. Eyre et al.
BLOOD ADVANCES (2021)
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
BLOOD (2020)
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Marijke Linschoten et al.
LANCET HAEMATOLOGY (2020)
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Yucai Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer
Enrique Soto-Perez-de-Celis et al.
LANCET ONCOLOGY (2018)
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Gustaaf W. van Imhoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
A. Kuhnl et al.
ANNALS OF ONCOLOGY (2017)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma
Alexandra Smith et al.
CANCER EPIDEMIOLOGY (2015)
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
Mehdi Hamadani et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic
Tanya M. Wildes et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Richard Delarue et al.
LANCET ONCOLOGY (2013)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)